Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38377
CAS Number:
80621-81-4
Rifaximine
Purity:
≥ 97 % (HPLC)
Documents
$144.12 /1G
Taille
Request Bulk Quote
Informations sur le produit

Rifaximin is a broad-spectrum antibiotic that is primarily used for the treatment of gastrointestinal infections, particularly those caused by non-invasive strains of Escherichia coli. Its unique mechanism of action, which involves inhibiting bacterial RNA synthesis, makes it effective against a variety of Gram-positive and Gram-negative bacteria. Rifaximin is particularly notable for its low systemic absorption, allowing it to act locally in the gut while minimizing potential side effects. This characteristic makes it an excellent choice for treating conditions such as traveler's diarrhea and irritable bowel syndrome with diarrhea (IBS-D).

In addition to its gastrointestinal applications, Rifaximin has shown promise in treating hepatic encephalopathy, helping to reduce the risk of recurrence in patients with liver disease. Its versatility and efficacy in various therapeutic areas highlight its importance in modern medicine. Researchers and healthcare professionals appreciate Rifaximin for its targeted action and favorable safety profile, making it a valuable tool in both clinical and research settings.

Numéro CAS 
80621-81-4
Formule moléculaire
C43H51N3O11
Poids moléculaire 
785.89
Point de fusion 
212 °C
Informations générales
Numéro CAS 
80621-81-4
Formule moléculaire
C43H51N3O11
Poids moléculaire 
785.89
Point de fusion 
212 °C
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Rifaximin is widely utilized in research focused on:

  • Antibiotic Treatment: Primarily used to treat gastrointestinal infections, Rifaximin is effective against certain strains of bacteria, making it a go-to option for conditions like traveler's diarrhea and irritable bowel syndrome.
  • Hepatic Encephalopathy Management: This compound helps reduce the risk of hepatic encephalopathy in patients with liver disease by decreasing the production of ammonia in the gut, thus improving overall patient outcomes.
  • Research in Gut Microbiome: Rifaximin is employed in studies examining the gut microbiome's role in health and disease, providing insights into how antibiotics can modulate gut flora and impact metabolic conditions.
  • Pharmaceutical Development: Its unique properties make Rifaximin a subject of interest in developing new formulations and delivery systems, enhancing the effectiveness of treatments for gastrointestinal disorders.
  • Cost-Effective Treatment Option: Compared to other antibiotics, Rifaximin often presents a lower risk of developing resistance, making it a more sustainable choice for long-term treatment regimens.

Citations